Summarized by Masters of Longevity from FDA - Drugs.
Unapproved GLP-1 medicines for weight loss are the focus, with an accessible look at safety and regulatory concerns readers should expect.
Key Takeaways
- The FDA warns that unapproved GLP-1 products lack established safety and effectiveness for weight loss.
- The agency highlights risks from informal sources including counterfeit, misbranded, or contaminated products.
- FDA urges reporting of adverse events and warns against obtaining these medicines outside licensed prescribers and pharmacies.
